(Reuters) – Bristol Myers Squibb said on Tuesday it will acquire radiopharmaceutical firm RayzeBio for about $4.1 billion.
Bristol said it will pay $62.50 for each share of RayzeBio in cash, representing a premium of 104% to stock’s last close.
RayzeBio shares were halted ahead of the deal announcement.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Krishna Chandra Eluri)
